Beneficial effects on serum lipoproteins by 17β-oestradiol-dydrogesterone therapy in postmenopausal women; a prospective study
Study objective: To study the possible changes of reproductive hormones, sex hormone binding globulin, serum lipids and lipoproteins, lipoprotein (a) included, coagulation and glucose in postmenopausal women treated with 17β-oestradiol and cyclic dydrogesterone for 14 days per 28 days treatment cycl...
Gespeichert in:
| Veröffentlicht in: | European journal of obstetrics & gynecology and reproductive biology 1992-11, Vol.47 (2), p.153-160 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 160 |
|---|---|
| container_issue | 2 |
| container_start_page | 153 |
| container_title | European journal of obstetrics & gynecology and reproductive biology |
| container_volume | 47 |
| creator | van der Mooren, Marius J. Demacker, Pierre N.M. Thomas, Chris M.G. Rolland, Rune |
| description | Study objective: To study the possible changes of reproductive hormones, sex hormone binding globulin, serum lipids and lipoproteins, lipoprotein (a) included, coagulation and glucose in postmenopausal women treated with 17β-oestradiol and cyclic dydrogesterone for 14 days per 28 days treatment cycle.
Design: Open longitudinal prospective study.
Duration: Twelve 28 days treatment cycles.
Setting: Gynaecological department of university hospital.
Subjects: 27 healthy postmenopausal women.
Results: After treatment for six cycles serum concentrations of FSH and LH decreased significantly with 43.0% and 24.4%, respectively. Serum concentrations of 17β-oestradiol and oestrone increased significantly with 302% and 792%, respectively, and SHBG increased as well with 111% (
P < 0.01). Serum total cholesterol decreased with 9.0% (
P < 0.01). Serum VLDL-cholesterol did not change significantly. Serum LDL-cholesterol decreased with 16.3% (
P < 0.01) and HDL-cholesterol increased with 8.0% (
P < 0.01). This was accompagnied with similar significant changes in the apolipoproteins: apolipoprotein A-I rose with 14.4% and apolipoprotein B decreased with 6.0%. Serum triglycerides and VLDL-triglycerides increased significantly with 14.4% and 17.9%, respectively. Lipoprotein (a) decreased with 17.5% (
P < 0.01). These results more or less sustained at cycle 12 of treatment. Serum concentrations of antithrombin III and glucose did not change. Fibrinogen decreased slightly but significantly below the initial value.
Conclusions: This combination replacement therapy gives beneficial changes in lipidmetabolism, indicating a reduced risk of developing coronary heart disease without unfavourably changing coagulation and glucose metabolism. The expected beneficial changes with oestradiol alone are not counteracted by the intermittent addition of dydrogesterone. Therefore this oestrogen/progestagen scheme can, indeed, be recommended for use in HRT. |
| doi_str_mv | 10.1016/0028-2243(92)90046-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73406608</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0028224392900462</els_id><sourcerecordid>73406608</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3472-6112fc14a48fb71a251d6d844cbc4870dbc50d356be808c8b92b04d9afc1ed563</originalsourceid><addsrcrecordid>eNp9kM-K1TAYxYMo453RN1DIQgZdVPOvaYIgjIN_Bgbc6DqkyVeNtElN2pGu5p18EJ9pcr0X3ZlN-PjOOTn5IfSEkpeUUPmKEKYaxgR_rtkLTYiQDbuHdlR1rOlkK-6jHeGENozS9iE6LeU7qYdzfYJOqGg1Z3qHbt9ChCG4YEcMwwBuKThFXCCvEx7DnOacFgix4H7DtPv9q0lQlmx9SGPjN5_T1zpDThHw8g2ynTccIp5TWSaIabZrqck_Ux1eY4trWpnrI-EGcFlWvz1CDwY7Fnh8vM_Ql_fvPl9-bK4_fbi6vLhuHBf1P5JSNjgqrFBD31HLWuqlV0K43gnVEd-7lnjeyh4UUU71mvVEeG2rCXwr-Rk6P-TWBj_WWtlMoTgYRxshrcV0XBApiapCcRC6WrVkGMycw2TzZigxe-5mz93suRvNzB_uhlXb02P-2k_g_5kOoOv-2XFvi7PjkG10ofyVCclbprsqe3OQQWVxEyCb4gJEBz7kis34FP7f4w6tSKIG</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73406608</pqid></control><display><type>article</type><title>Beneficial effects on serum lipoproteins by 17β-oestradiol-dydrogesterone therapy in postmenopausal women; a prospective study</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>van der Mooren, Marius J. ; Demacker, Pierre N.M. ; Thomas, Chris M.G. ; Rolland, Rune</creator><creatorcontrib>van der Mooren, Marius J. ; Demacker, Pierre N.M. ; Thomas, Chris M.G. ; Rolland, Rune</creatorcontrib><description>Study objective: To study the possible changes of reproductive hormones, sex hormone binding globulin, serum lipids and lipoproteins, lipoprotein (a) included, coagulation and glucose in postmenopausal women treated with 17β-oestradiol and cyclic dydrogesterone for 14 days per 28 days treatment cycle.
Design: Open longitudinal prospective study.
Duration: Twelve 28 days treatment cycles.
Setting: Gynaecological department of university hospital.
Subjects: 27 healthy postmenopausal women.
Results: After treatment for six cycles serum concentrations of FSH and LH decreased significantly with 43.0% and 24.4%, respectively. Serum concentrations of 17β-oestradiol and oestrone increased significantly with 302% and 792%, respectively, and SHBG increased as well with 111% (
P < 0.01). Serum total cholesterol decreased with 9.0% (
P < 0.01). Serum VLDL-cholesterol did not change significantly. Serum LDL-cholesterol decreased with 16.3% (
P < 0.01) and HDL-cholesterol increased with 8.0% (
P < 0.01). This was accompagnied with similar significant changes in the apolipoproteins: apolipoprotein A-I rose with 14.4% and apolipoprotein B decreased with 6.0%. Serum triglycerides and VLDL-triglycerides increased significantly with 14.4% and 17.9%, respectively. Lipoprotein (a) decreased with 17.5% (
P < 0.01). These results more or less sustained at cycle 12 of treatment. Serum concentrations of antithrombin III and glucose did not change. Fibrinogen decreased slightly but significantly below the initial value.
Conclusions: This combination replacement therapy gives beneficial changes in lipidmetabolism, indicating a reduced risk of developing coronary heart disease without unfavourably changing coagulation and glucose metabolism. The expected beneficial changes with oestradiol alone are not counteracted by the intermittent addition of dydrogesterone. Therefore this oestrogen/progestagen scheme can, indeed, be recommended for use in HRT.</description><identifier>ISSN: 0301-2115</identifier><identifier>EISSN: 1872-7654</identifier><identifier>DOI: 10.1016/0028-2243(92)90046-2</identifier><identifier>PMID: 1459329</identifier><identifier>CODEN: EOGRAL</identifier><language>eng</language><publisher>Shannon: Elsevier Ireland Ltd</publisher><subject>Apolipoproteins A - analysis ; Apolipoproteins B - blood ; Biological and medical sciences ; Cholesterol, HDL - blood ; Cholesterol, LDL - blood ; Cholesterol, VLDL - blood ; Coronary heart disease ; Drug Therapy, Combination ; Dydrogesterone ; Dydrogesterone - administration & dosage ; Dydrogesterone - therapeutic use ; Estradiol - administration & dosage ; Estradiol - blood ; Estradiol - therapeutic use ; Estrogen Replacement Therapy ; Estrone - blood ; Female ; Follicle Stimulating Hormone - blood ; Genital system. Reproduction ; Hormone replacement therapy ; Humans ; Lipidmetabolism ; Lipoprotein ; Lipoprotein(a) - blood ; Lipoproteins - blood ; Luteinizing Hormone - blood ; Medical sciences ; Menopause - physiology ; Middle Aged ; Oestradiol ; Pharmacology. Drug treatments ; Postmenopause ; Prospective Studies ; Triglycerides - blood</subject><ispartof>European journal of obstetrics & gynecology and reproductive biology, 1992-11, Vol.47 (2), p.153-160</ispartof><rights>1992</rights><rights>1993 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3472-6112fc14a48fb71a251d6d844cbc4870dbc50d356be808c8b92b04d9afc1ed563</citedby><cites>FETCH-LOGICAL-c3472-6112fc14a48fb71a251d6d844cbc4870dbc50d356be808c8b92b04d9afc1ed563</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/0028224392900462$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4635297$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1459329$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>van der Mooren, Marius J.</creatorcontrib><creatorcontrib>Demacker, Pierre N.M.</creatorcontrib><creatorcontrib>Thomas, Chris M.G.</creatorcontrib><creatorcontrib>Rolland, Rune</creatorcontrib><title>Beneficial effects on serum lipoproteins by 17β-oestradiol-dydrogesterone therapy in postmenopausal women; a prospective study</title><title>European journal of obstetrics & gynecology and reproductive biology</title><addtitle>Eur J Obstet Gynecol Reprod Biol</addtitle><description>Study objective: To study the possible changes of reproductive hormones, sex hormone binding globulin, serum lipids and lipoproteins, lipoprotein (a) included, coagulation and glucose in postmenopausal women treated with 17β-oestradiol and cyclic dydrogesterone for 14 days per 28 days treatment cycle.
Design: Open longitudinal prospective study.
Duration: Twelve 28 days treatment cycles.
Setting: Gynaecological department of university hospital.
Subjects: 27 healthy postmenopausal women.
Results: After treatment for six cycles serum concentrations of FSH and LH decreased significantly with 43.0% and 24.4%, respectively. Serum concentrations of 17β-oestradiol and oestrone increased significantly with 302% and 792%, respectively, and SHBG increased as well with 111% (
P < 0.01). Serum total cholesterol decreased with 9.0% (
P < 0.01). Serum VLDL-cholesterol did not change significantly. Serum LDL-cholesterol decreased with 16.3% (
P < 0.01) and HDL-cholesterol increased with 8.0% (
P < 0.01). This was accompagnied with similar significant changes in the apolipoproteins: apolipoprotein A-I rose with 14.4% and apolipoprotein B decreased with 6.0%. Serum triglycerides and VLDL-triglycerides increased significantly with 14.4% and 17.9%, respectively. Lipoprotein (a) decreased with 17.5% (
P < 0.01). These results more or less sustained at cycle 12 of treatment. Serum concentrations of antithrombin III and glucose did not change. Fibrinogen decreased slightly but significantly below the initial value.
Conclusions: This combination replacement therapy gives beneficial changes in lipidmetabolism, indicating a reduced risk of developing coronary heart disease without unfavourably changing coagulation and glucose metabolism. The expected beneficial changes with oestradiol alone are not counteracted by the intermittent addition of dydrogesterone. Therefore this oestrogen/progestagen scheme can, indeed, be recommended for use in HRT.</description><subject>Apolipoproteins A - analysis</subject><subject>Apolipoproteins B - blood</subject><subject>Biological and medical sciences</subject><subject>Cholesterol, HDL - blood</subject><subject>Cholesterol, LDL - blood</subject><subject>Cholesterol, VLDL - blood</subject><subject>Coronary heart disease</subject><subject>Drug Therapy, Combination</subject><subject>Dydrogesterone</subject><subject>Dydrogesterone - administration & dosage</subject><subject>Dydrogesterone - therapeutic use</subject><subject>Estradiol - administration & dosage</subject><subject>Estradiol - blood</subject><subject>Estradiol - therapeutic use</subject><subject>Estrogen Replacement Therapy</subject><subject>Estrone - blood</subject><subject>Female</subject><subject>Follicle Stimulating Hormone - blood</subject><subject>Genital system. Reproduction</subject><subject>Hormone replacement therapy</subject><subject>Humans</subject><subject>Lipidmetabolism</subject><subject>Lipoprotein</subject><subject>Lipoprotein(a) - blood</subject><subject>Lipoproteins - blood</subject><subject>Luteinizing Hormone - blood</subject><subject>Medical sciences</subject><subject>Menopause - physiology</subject><subject>Middle Aged</subject><subject>Oestradiol</subject><subject>Pharmacology. Drug treatments</subject><subject>Postmenopause</subject><subject>Prospective Studies</subject><subject>Triglycerides - blood</subject><issn>0301-2115</issn><issn>1872-7654</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kM-K1TAYxYMo453RN1DIQgZdVPOvaYIgjIN_Bgbc6DqkyVeNtElN2pGu5p18EJ9pcr0X3ZlN-PjOOTn5IfSEkpeUUPmKEKYaxgR_rtkLTYiQDbuHdlR1rOlkK-6jHeGENozS9iE6LeU7qYdzfYJOqGg1Z3qHbt9ChCG4YEcMwwBuKThFXCCvEx7DnOacFgix4H7DtPv9q0lQlmx9SGPjN5_T1zpDThHw8g2ynTccIp5TWSaIabZrqck_Ux1eY4trWpnrI-EGcFlWvz1CDwY7Fnh8vM_Ql_fvPl9-bK4_fbi6vLhuHBf1P5JSNjgqrFBD31HLWuqlV0K43gnVEd-7lnjeyh4UUU71mvVEeG2rCXwr-Rk6P-TWBj_WWtlMoTgYRxshrcV0XBApiapCcRC6WrVkGMycw2TzZigxe-5mz93suRvNzB_uhlXb02P-2k_g_5kOoOv-2XFvi7PjkG10ofyVCclbprsqe3OQQWVxEyCb4gJEBz7kis34FP7f4w6tSKIG</recordid><startdate>19921119</startdate><enddate>19921119</enddate><creator>van der Mooren, Marius J.</creator><creator>Demacker, Pierre N.M.</creator><creator>Thomas, Chris M.G.</creator><creator>Rolland, Rune</creator><general>Elsevier Ireland Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19921119</creationdate><title>Beneficial effects on serum lipoproteins by 17β-oestradiol-dydrogesterone therapy in postmenopausal women; a prospective study</title><author>van der Mooren, Marius J. ; Demacker, Pierre N.M. ; Thomas, Chris M.G. ; Rolland, Rune</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3472-6112fc14a48fb71a251d6d844cbc4870dbc50d356be808c8b92b04d9afc1ed563</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>Apolipoproteins A - analysis</topic><topic>Apolipoproteins B - blood</topic><topic>Biological and medical sciences</topic><topic>Cholesterol, HDL - blood</topic><topic>Cholesterol, LDL - blood</topic><topic>Cholesterol, VLDL - blood</topic><topic>Coronary heart disease</topic><topic>Drug Therapy, Combination</topic><topic>Dydrogesterone</topic><topic>Dydrogesterone - administration & dosage</topic><topic>Dydrogesterone - therapeutic use</topic><topic>Estradiol - administration & dosage</topic><topic>Estradiol - blood</topic><topic>Estradiol - therapeutic use</topic><topic>Estrogen Replacement Therapy</topic><topic>Estrone - blood</topic><topic>Female</topic><topic>Follicle Stimulating Hormone - blood</topic><topic>Genital system. Reproduction</topic><topic>Hormone replacement therapy</topic><topic>Humans</topic><topic>Lipidmetabolism</topic><topic>Lipoprotein</topic><topic>Lipoprotein(a) - blood</topic><topic>Lipoproteins - blood</topic><topic>Luteinizing Hormone - blood</topic><topic>Medical sciences</topic><topic>Menopause - physiology</topic><topic>Middle Aged</topic><topic>Oestradiol</topic><topic>Pharmacology. Drug treatments</topic><topic>Postmenopause</topic><topic>Prospective Studies</topic><topic>Triglycerides - blood</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>van der Mooren, Marius J.</creatorcontrib><creatorcontrib>Demacker, Pierre N.M.</creatorcontrib><creatorcontrib>Thomas, Chris M.G.</creatorcontrib><creatorcontrib>Rolland, Rune</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of obstetrics & gynecology and reproductive biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>van der Mooren, Marius J.</au><au>Demacker, Pierre N.M.</au><au>Thomas, Chris M.G.</au><au>Rolland, Rune</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Beneficial effects on serum lipoproteins by 17β-oestradiol-dydrogesterone therapy in postmenopausal women; a prospective study</atitle><jtitle>European journal of obstetrics & gynecology and reproductive biology</jtitle><addtitle>Eur J Obstet Gynecol Reprod Biol</addtitle><date>1992-11-19</date><risdate>1992</risdate><volume>47</volume><issue>2</issue><spage>153</spage><epage>160</epage><pages>153-160</pages><issn>0301-2115</issn><eissn>1872-7654</eissn><coden>EOGRAL</coden><abstract>Study objective: To study the possible changes of reproductive hormones, sex hormone binding globulin, serum lipids and lipoproteins, lipoprotein (a) included, coagulation and glucose in postmenopausal women treated with 17β-oestradiol and cyclic dydrogesterone for 14 days per 28 days treatment cycle.
Design: Open longitudinal prospective study.
Duration: Twelve 28 days treatment cycles.
Setting: Gynaecological department of university hospital.
Subjects: 27 healthy postmenopausal women.
Results: After treatment for six cycles serum concentrations of FSH and LH decreased significantly with 43.0% and 24.4%, respectively. Serum concentrations of 17β-oestradiol and oestrone increased significantly with 302% and 792%, respectively, and SHBG increased as well with 111% (
P < 0.01). Serum total cholesterol decreased with 9.0% (
P < 0.01). Serum VLDL-cholesterol did not change significantly. Serum LDL-cholesterol decreased with 16.3% (
P < 0.01) and HDL-cholesterol increased with 8.0% (
P < 0.01). This was accompagnied with similar significant changes in the apolipoproteins: apolipoprotein A-I rose with 14.4% and apolipoprotein B decreased with 6.0%. Serum triglycerides and VLDL-triglycerides increased significantly with 14.4% and 17.9%, respectively. Lipoprotein (a) decreased with 17.5% (
P < 0.01). These results more or less sustained at cycle 12 of treatment. Serum concentrations of antithrombin III and glucose did not change. Fibrinogen decreased slightly but significantly below the initial value.
Conclusions: This combination replacement therapy gives beneficial changes in lipidmetabolism, indicating a reduced risk of developing coronary heart disease without unfavourably changing coagulation and glucose metabolism. The expected beneficial changes with oestradiol alone are not counteracted by the intermittent addition of dydrogesterone. Therefore this oestrogen/progestagen scheme can, indeed, be recommended for use in HRT.</abstract><cop>Shannon</cop><pub>Elsevier Ireland Ltd</pub><pmid>1459329</pmid><doi>10.1016/0028-2243(92)90046-2</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0301-2115 |
| ispartof | European journal of obstetrics & gynecology and reproductive biology, 1992-11, Vol.47 (2), p.153-160 |
| issn | 0301-2115 1872-7654 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_73406608 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Apolipoproteins A - analysis Apolipoproteins B - blood Biological and medical sciences Cholesterol, HDL - blood Cholesterol, LDL - blood Cholesterol, VLDL - blood Coronary heart disease Drug Therapy, Combination Dydrogesterone Dydrogesterone - administration & dosage Dydrogesterone - therapeutic use Estradiol - administration & dosage Estradiol - blood Estradiol - therapeutic use Estrogen Replacement Therapy Estrone - blood Female Follicle Stimulating Hormone - blood Genital system. Reproduction Hormone replacement therapy Humans Lipidmetabolism Lipoprotein Lipoprotein(a) - blood Lipoproteins - blood Luteinizing Hormone - blood Medical sciences Menopause - physiology Middle Aged Oestradiol Pharmacology. Drug treatments Postmenopause Prospective Studies Triglycerides - blood |
| title | Beneficial effects on serum lipoproteins by 17β-oestradiol-dydrogesterone therapy in postmenopausal women; a prospective study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T02%3A57%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Beneficial%20effects%20on%20serum%20lipoproteins%20by%2017%CE%B2-oestradiol-dydrogesterone%20therapy%20in%20postmenopausal%20women;%20a%20prospective%20study&rft.jtitle=European%20journal%20of%20obstetrics%20&%20gynecology%20and%20reproductive%20biology&rft.au=van%20der%20Mooren,%20Marius%20J.&rft.date=1992-11-19&rft.volume=47&rft.issue=2&rft.spage=153&rft.epage=160&rft.pages=153-160&rft.issn=0301-2115&rft.eissn=1872-7654&rft.coden=EOGRAL&rft_id=info:doi/10.1016/0028-2243(92)90046-2&rft_dat=%3Cproquest_cross%3E73406608%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=73406608&rft_id=info:pmid/1459329&rft_els_id=0028224392900462&rfr_iscdi=true |